Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.

Diverging Cost Trends in Pharma Giants: Bausch vs. Halozyme

__timestampBausch Health Companies Inc.Halozyme Therapeutics, Inc.
Wednesday, January 1, 2014225460000022732000
Thursday, January 1, 2015264500000029245000
Friday, January 1, 2016261100000033206000
Sunday, January 1, 2017254800000031152000
Monday, January 1, 2018235100000010136000
Tuesday, January 1, 2019235000000045546000
Wednesday, January 1, 2020224900000043367000
Friday, January 1, 2021239400000081413000
Saturday, January 1, 20222364000000139304000
Sunday, January 1, 20232559000000192361000
Monday, January 1, 2024159417000
Loading chart...

Unleashing insights

Cost of Revenue Trends: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding cost dynamics is crucial. Over the past decade, Bausch Health Companies Inc. and Halozyme Therapeutics, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Bausch Health's cost of revenue has remained relatively stable, averaging around $2.4 billion annually, with a slight increase of approximately 13% by 2023. In contrast, Halozyme Therapeutics has experienced a dramatic rise, with costs surging by over 740% from 2014 to 2023. This stark difference highlights the diverse strategies and market conditions faced by these companies. While Bausch Health maintains a steady course, Halozyme's growth trajectory suggests aggressive expansion and investment. As the pharmaceutical sector continues to innovate, these trends offer valuable insights into the financial strategies shaping the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025